ArticleOPEN ACCESS

Dissecting complement blockade for clinic use

Blood
DOI: 10.1182/blood-2014-12-616300
17Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Peffault de Latour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment. This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients which shows that CH50 is a promising biomarker of therapeutic complement blockade.

Cite

CITATION STYLE

APA

Risitano, A. M. (2015, January 29). Dissecting complement blockade for clinic use. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-12-616300

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free